End Stage Renal Diseases Clinical Trial
Official title:
Evaluation of a Marine OXYgen Carrier: HEMO2Life® for hypOthermic Kidney Graft Preservation, Before Transplantation
Kidney transplantation is the treatment of choice for end stage renal diseases, increasing
life expectancy and quality of life. Improvement in organ preservation is a critical issue in
this context.
This is a safety study evaluating the use of an oxygen carrier HEMO2Life® as an additive in
organ preservation solution in kidney transplantation.
Security of the use of HEMO2Life® will be analyzed by collecting all events within the first
3 months in terms of :
1. HEMO2Life® adverse effects
2. graft safety
3. recipient safety (any adverse event) Accountability search will be achieved for each of
these events.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04141358 -
Advanced Ultrasound Applications for Predicting AVF Outcomes
|
||
| Completed |
NCT04181710 -
Evaluation of a Marine OXYgen Carrier for Organ Preservation
|
N/A |